


"I am impressed by the quick transformation happening in India," - Cory Card, senior development team leader, R&D, HyClone

11 April 2005 | News




How has the merger with Millipore affected the fortunes of HyClone?

It was not a merger we had with Millipore. It is simply a partnership with them on certain products to be used together. In fact, the life sciences division of Fisher acquired us way back in August 2003.

Can we expect the partnership with Millipore to turn into a single entity?

No. Actually, we had similar partnerships with a lot of other companies as well and still remain as separate entities eventually. We leverage the product base of both companies and try coming out with products jointly benefiting users.



What is your feedback on the Indian industry?

It is quite good. We are presently with two Indian distributors. We have had some really good successes through them. But now I am seeing personally how Indian biotech industry has come of age. I am impressed by the quick transformation happening here and with certain things like IP protection and regulatory issues given due importance, there would be much more development taking place.

What are the new products and technologies being worked upon?

We are presently working on some of the major next generation platforms for gene therapy, vaccine production etc. Besides we also enter into strategic alliances with other companies to exchange and transfer the product base and technology.